There is little agreement on the most effective and safest treatment for feline demodicosis. Protocols generally consist of long-lasting therapy courses based on rinses, subcutaneous injections, oral drug administration or repeated spot-on formulation and the efficacy of most of these is poorly documented.
INTRODUCTION
Feline demodicosis is a rare parasitic dermatitis caused by three different Demodex species: Demodex cati , Demodex gatoi and a third unnamed species (Ferreira et al . 2015 ) . D . cati is the most common species and it is responsible for localised or generalised infestations, usually associated with underlying diseases or immunosuppressive therapies (Guaguére et al . 2004 , Bizikova 2014 .
Several medications have been reported for the treatment of feline demodicosis with variable outcome, depending on the causative agent and on the frequency and dosage of drug administration (Foley 1995 , Vogelnest 2001 , Johnstone 2002 , Mueller 2004 , Löwenstein et al . 2005 , Morris & Beale 2006 , Saari et al . 2009 , Beale 2012 , Bizikova 2014 , Short & Gram 2016 . The drug most frequently used is 2% lime sulphur, which was shown to be effective in treating both Demodex cati and Demodex gatoi (Foley 1995 , Mueller 2004 , Newbury et al . 2006 , Saari et al . 2009 , Beale 2012 . In a systematic review on treatment of demodicosis, Mueller ( 2004 ) reported good evidence of efficacy, with a failure rate of 12% of cases. Protocols comprise a minimum of four to six weekly dips, which can be time consuming and not easy in cats (Mueller 2004 ) . Unfortunately, the product is not universally available and side effects have been observed, such as excessive skin drying and irritation, yellow staining of light coats, hair loss, gastrointestinal signs and oral ulcerations (Moriello & DeBoer 1995 , Newbury et al . 2007 ). Other reported treatments, with only fair evidence of efficacy, include 0·0125 to 0·025% amitraz rinses (seemingly effective both for D . cati and D . gatoi , but potentially toxic in cats), and macrocyclic lactones. Injectable or oral ivermectin was described to be effective against both mites, with some reported failures in D . gatoi (Löwenstein et al . 2005 , Morris & Beale 2006 , Newbury et al . 2006 , Saari et al . 2009 , Beale 2012 . Injectable weekly doramectin was showed to be effective against D . cati , with no reported use for D . gatoi (Johnstone 2002 , Mueller 2004 . Serious central nervous system toxicity was observed with both ivermectin and doramectin (Löwenstein et al . 2005 Daily oral dose of 1 to 1·5 mg/kg milbemycin oxime was shown to be effective against D . cati when administered for 8 to 27 weeks but neurological signs were observed (Vogelnest 2001 , Bizikova 2014 . Weekly application of a topical 10% imidacloprid/1% moxidectin combination for eight weeks was reported to be effective in treating D . gatoi , while monthly selamectin was unsuccessful for the same species, which is commonly considered to be more resistant to treatment with macrocyclic lactones than D . cati (Saari et al . 2009 , Beale 2012 , Short & Gram 2016 . Due to the paucity of cases reported, data on the efficacy and safety of these protocols is not clearly established.
In contrast to cats, there are plenty of protocols for the treatment of demodicosis in dogs. Recently isoxazolines, new parasiticites that are potent inhibitors of γ -aminobutyric acid-gated chloride and l-glutamate-gated chloride channels, were released in the market for canine use (Gassel et al . 2014 ) . Among these molecules, orally administered 25 to 50 mg/kg fluralaner (Bravecto ® Chews For Dogs, MSD Animal Health) showed high efficacy and safety in treating dogs with generalised demodicosis (Fourie et al . 2015 ) . The off-label use of oral fluralaner in cats has been previously reported where it was shown to be safe and effective when used for the treatment of the fur mite Lynxacarus radowsky in cats (Han & Noli 2016 ) .
This case report describes the successful treatment of a case of feline generalised demodicosis caused by Demodex cati , with an single oral dose of 28 mg/kg fluralaner. As far as we know this is the first report describing the use of fluralaner for the treatment of feline demodicosis.
CASE HISTORY
A 12-year-old, 4 kg, spayed female short-haired cat was presented with a two-month history of a severe generalised dermatitis. For the past two years, the cat had been suffering from recurrent stomatitis and had been repeatedly treated with intramuscular injections of 5 mg/kg methylprednisolone acetate (Depomedrol Vet ® , Zoetis) every two to three months. The latest injection had been administered two months before referral. In that same period the cat developed crusts on the chin, pruritus and alopecia progressively involving the muzzle and forelegs. Eventually, it became anorexic. Treatment with a 10-day course of injectable amoxicillin (dosage unknown) did not resolve the dermatologic condition. Blood biochemistry, thoracic radiographs and abdominal ultrasound examination were unremarkable. Tests for feline immunodeficiency virus and feline leukaemia virus were negative.
On clinical presentation the cat was lethargic but in good body condition. Inspection of the oral cavity revealed mild stomatitis and faucitis. The dermatological examination showed alopecia and comedones involving the chin and lips. Alopecia, marked erythema and papules were present in the periocular areas and on the dorsal nose.
Partial alopecia and erythema was observed also on the thoracic limbs (Fig 1 ) . Mild pruritus, mainly of the facial and antebrachial regions, was reported by the owners. Microscopic examination of plucked hair and multiple skin scrapings from the affected areas revealed numerous adult mites of Demodex cati , few eggs and no fungal elements. Fungal cultures were negative for dermatophytes. Cytology from the papules identified a high number of intracellular cocci in neutrophils. The final diagnosis was feline demodicosis due to Demodex cati and secondary bacterial infection most probably triggered by prolonged glucocorticoid therapy.
As there are no licensed products for treating feline demodicosis in Italy, the patient was administered 112·5 mg of fluralaner orally as a single dose. About 8 mg/kg cefovecin (Convenia ® , Zoetis) was administered subcutaneously to resolve the bacterial infection and 0·05 mg/kg oral meloxicam was prescribed once daily for five days to reduce oral inflammation. The use of methylprednisolone acetate was promptly discontinued and no further treatments were given thereafter.
One month later the pruritus stopped. Partial regrowth of the hair was observed in the periocular areas and antebrachial areas and erythema was less evident. There were still comedones and alopecia on the chin and lower lip. Microscopic examination of multiple skin scrapings from the muzzle, chin and antebrachial areas did not reveal Demodex mites. Inspection of the oral cavity still showed oropharyngeal inflammation but the owner reported that the cat ate normally.
At the following recheck, two months after administration of fluralaner, the hair had completely regrown on all previously affected areas (Fig 2 ) with only few comedones still visible on FIG 1 . Alopecia, marked erythema and papules on the dorsal nasal region and periocular skin of a cat affected with generalised demodicosis due to Demodex cati the chin. Skin scrapings from these areas were negative again for the presence of mites. The cat remained healthy for a follow-up period of five months and a specialist consultation was advised to prevent relapse of the oral disease.
DISCUSSION
This case report describes the successful use of fluralaner in the treatment of a cat with a generalised demodicosis caused by Demodex cati . Although feline demodicosis is a rare parasitic skin disease it should be always considered as a possible consequence of chronic systemic or topical glucocorticoid treatment (Guaguére et al . 2004 , Bizikova 2014 . At the time of presentation, the patient showed no signs of hyperglucocorticism, or any significant variation in the biochemistry panel. However, as no other internal diseases were found, generalised demodicosis was considered to be due to the suppressive effects of steroids on the immune system.
The treatment of generalised demodicosis in dogs has been recently enhanced by the introduction of isoxazolines, which are now widely used as an alternative to macrocyclic lactones. These molecules are considered very safe in mammals (Fourie et al . 2015 , Beugnet et al . 2016 , Six et al . 2016 . Recently, the pharmacokinetic of fluralaner has been shown to be comparable in dogs and cats after topical and intravenous administration and a novel spot-on formulation for cats will soon be available for treatment against fleas and ticks ( Kilp et al . 2016 ) .
We administered fluralaner once at the same dose labelled for dogs and found it effective against Demodex cati . No side effects were observed, in agreement with Han & Noli ( 2016 ) , who successfully treated ten cats affected with Lynxacarus radowsky with a similar dosage. A single dose regimen is an attractive therapeutic option for cats, which are often reluctant to receive longlasting treatments based on rinses, injections or daily oral drug administration.
Because fluralaner administration commenced at the same time as methylprednisolone acetate injections were discontinued, we cannot exclude the possibility that the cat underwent spontaneous resolution because of the restoration of its immune system functionality. However, no cases of spontaneous resolution of adult-onset generalised demodicosis have previously been reported.
CONCLUSION
In this case report, one single dose of 28 mg/kg fluralaner, administered orally was effective in treating a case of feline generalised demodicosis caused by Demodex cati that had likely been triggered by prolonged glucocorticoid administration. In view of the lack of side effects, fluralaner may represent an attractive option for treating generalised demodicosis in feline patients.
